DEVELOPING AND VALIDATING A DISASTER MANAGEMENT ASSESSMENT TOOL FOR HEALTHCARE PRACTITIONERS
6ER-042
THE DISASTER PREPAREDNESS AND MANAGEMENT OF HEALTHCARE PRACTITIONERS: A SYSTEMATIC REVIEW OF THE ASSESSMENT INSTRUMENTS
6ER-041
ROLE OF CHECKPOINT INHIBITORS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA
6ER-040
A TOOL PROPOSAL FOR IDENTIFYING THE RISK OF POLYPHARMACY IN NURSING HOMES FOR ELDERLY PEOPLE
6ER-039
PAIN MANAGEMENT: OPIOID USE IN HOSPITALS
6ER-038
ELABORATION OF A COMPETENCY FRAMEWORK FOR PATIENTS UNDERGOING PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE OR ATRIAL SEPTAL DEFECT
6ER-037
PHARMACO-UTILISATION OF IBRUTINIB IN CLL: A SINGLE CENTRE STUDY
6ER-036
EVALUATION OF THE EFFICACY OF NEOADJUVANCE TREATMENT WITH IMMUNOTHERAPY IN EARLY STAGE BREAST CANCER: A SYSTEMATIC REVIEW
6ER-035
EXAMINING THE PERCEPTIONS OF PHARMACISTS OF JOB SATISFACTION, ACHIEVMENTS, AND PREPRDNESS
6ER-034
EFFICACY OF NEOADJUVANT TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER IN EARLY STAGES: A SYSTEMATIC REVIEW
6ER-033
ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥1%
6ER-032
ADJUSTED INDIRECT COMPARISON OF CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VS. IMMUNOTHERAPY ALONE IN THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH PD-L1≥50%
6ER-031
EXCLUSION OF PEOPLE LIVING WITH HIV FROM ONCOHAEMATOLOGICAL CLINICAL TRIALS WITH IMMUNE CHECKPOINT INHIBITORS
6ER-030
EVALUATION OF A GROUP-BASED ONLINE INFORMED CONSENT CONVERSATION (ECONSENT) IN PARTICIPANTS FROM A VACCINATION CLINICAL TRIAL: A MIXED METHOD STUDY
6ER-029
A SYSTEMATIC REVIEW OF COMBINED POLY (ADP-RIBOSE) POLYMERASE INHIBITOR AND ANDROGEN RECEPTOR ANTAGONISTS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.
